Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
Summit Therapeutics (NASDAQ: SMMT) is one of those stocks that have been quite explosive: The share price of the clinical-stage drugmaker has skyrocketed by nearly 390% over the last 12 months. But is Summit Therapeutics a millionaire-maker? We can explain Summit Therapeutics' remarkable stock performance with just one word: ivonescimab. That's the cancer drug Summit licensed from Chinese drugmaker Akeso (OTC: AKES.F) in 2022. Ivonescimab works in two ways. It blocks the PD-1 proteins that some cancer cells use to hide from the body's immune system. The drug also blocks vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels that enable tumors to grow. Summit's share price took off last year after Akeso reported spectacular results from a late-stage clinical trial that evaluated ivonescimab as a first-line treatment for non-small cell lung cancer (NSCLC). The drug outperformed Merck 's Keytruda (the world's top-selling drug in 2024) in
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.MarketBeat
- Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.MarketBeat
- Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
SMMT
Earnings
- 10/20/25 - Beat
SMMT
Sec Filings
- 11/7/25 - Form 8-K
- 10/29/25 - Form S-3ASR
- 10/23/25 - Form 4
- SMMT's page on the SEC website